Condensed Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Series A preferred stock (if converted) Preferred Stock	Series A Warrants Common Stock	Series A Warrants Additional Paid-in Capital	Series B Warrants Common Stock	Series B Warrants Additional Paid-in Capital	Common Stock TardiMed	Common Stock	Additional Paid-in Capital TardiMed	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning Balance at Dec. 31, 2020	$ 1,909,805						$ 27,132		$ 25,826,295	$ (18,245,396)	$ 7,608,031
Beginning Balance (in shares) at Dec. 31, 2020	1,819						542,648
Increase (decrease) in stockholders' equity
Accrued dividend series A preferred stock	$ 108,858								(108,858)		(108,858)
Exercise of common warrants		$ 2,060	$ (2,060)	$ 7,468	$ (7,468)
Exercise of common warrants (in shares)		41,192		149,353
Stock-based compensation									295,684		295,684
Net loss										(7,845,867)	(7,845,867)
Ending Balance at Sep. 30, 2021	$ 2,018,663						$ 36,660		26,003,593	(26,091,263)	(51,010)
Ending Balance (in shares) at Sep. 30, 2021	1,819						733,194
Beginning Balance at Jun. 30, 2021	$ 1,981,978						$ 36,660		25,852,542	(23,085,859)	2,803,343
Beginning Balance (in shares) at Jun. 30, 2021	1,819						733,194
Increase (decrease) in stockholders' equity
Accrued dividend series A preferred stock	$ 36,685								(36,685)		(36,685)
Stock-based compensation									187,736		187,736
Net loss										(3,005,404)	(3,005,404)
Ending Balance at Sep. 30, 2021	$ 2,018,663						$ 36,660		26,003,593	(26,091,263)	(51,010)
Ending Balance (in shares) at Sep. 30, 2021	1,819						733,194
Beginning Balance at Dec. 31, 2021							$ 63,619		42,087,719	(28,884,542)	13,266,796
Beginning Balance (in shares) at Dec. 31, 2021							1,272,383
Increase (decrease) in stockholders' equity
Issuance of common stock and warrants, net of issuance costs							$ 66,667		6,871,817		6,938,484
Issuance of common stock and warrants, net of issuance costs (in shares)							1,333,333
Exercise of common warrants							$ 1,200		142,800		144,000
Exercise of common warrants (in shares)							24,000
Exercise of VARs							$ 60		(60)
Exercise of VARs (in shares)							1,194
Stock-based compensation							$ 187		876,569		876,756
Stock-based compensation (in shares)							3,750
Conversion of Redeemable Series A Convertible Preferred Stock									2,163,937		2,163,937
Exercise of TardiMed Warrants						$ 1,810		$ (1,810)
Exercise of TardiMed Warrants (in shares)						36,196
Net loss										(15,756,665)	(15,756,665)
Ending Balance at Sep. 30, 2022							$ 133,543		52,140,972	(44,641,207)	7,633,308
Ending Balance (in shares) at Sep. 30, 2022							2,670,856
Beginning Balance at Jun. 30, 2022							$ 63,754		42,739,793	(41,453,932)	1,349,615
Beginning Balance (in shares) at Jun. 30, 2022							1,275,077
Increase (decrease) in stockholders' equity
Issuance of common stock and warrants, net of issuance costs							$ 66,667		6,871,817		6,938,484
Issuance of common stock and warrants, net of issuance costs (in shares)							1,333,333
Exercise of common warrants							$ 1,200		142,800		144,000
Exercise of common warrants (in shares)							24,000
Stock-based compensation							$ 113		224,434		224,547
Stock-based compensation (in shares)							2,250
Conversion of Redeemable Series A Convertible Preferred Stock									2,163,937		2,163,937
Exercise of TardiMed Warrants						$ 1,810		$ (1,810)
Exercise of TardiMed Warrants (in shares)						36,196
Net loss										(3,187,275)	(3,187,275)
Ending Balance at Sep. 30, 2022							$ 133,543		$ 52,140,972	$ (44,641,207)	$ 7,633,308
Ending Balance (in shares) at Sep. 30, 2022							2,670,856